Nurse Practitioner Program year 2025 Reported 2021–2025 Source: CMS Open Payments, 2026 publication

Melissa Ridella

Nurse Practitioner, Family Henderson, NV Nurse Practitioner

NPI 1568006864 CMS profile 11247424

1748 W Horizon Ridge Pkwy, Henderson, NV 89012

Open in the dashboard

General payments

$5,802

320 records reported · program years 2021–2025

Research payments

$0

Paid to them · None reported · program years 2021–2025

Ownership & investment interest

$0

None reported

Through program year 2025, Melissa Ridella of Henderson, NV is reported in the CMS Open Payments database as having received $5,802 across 320 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 95th percentile of Nurse Practitioner, Family profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

5 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $1,542 80
2024 General $1,761 92
2023 General $1,371 80
2022 General $688 37
2021 General $440 31

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Melissa Ridella
  • Nurse Practitioner, Family median
  • Middle half of Nurse Practitioner, Family
  • National median

In program year 2025, general payments to Melissa Ridella were reported at $1,542. Among 107,232 Nurse Practitioner, Family profiles paid that year, the median was $168 and the middle half received between $53 and $521.

Show as a table
Year Melissa Ridella Nurse Practitioner, Family median Middle half National median
2019 $0 $39 $18–$91 $163
2020 $0 $32 $17–$76 $114
2021 $440 $124 $35–$379 $132
2022 $688 $141 $44–$430 $149
2023 $1,371 $154 $49–$476 $160
2024 $1,761 $165 $51–$504 $164
2025 $1,542 $168 $53–$521 $169

Breakdown

Who paid General payments · program years 2021–2025
  1. AbbVie, Inc. $1,234 78 payments
  2. Salix Pharmaceuticals, a division of Bausch Health US, LLC $1,153 64 payments
  3. Forte Bio-Pharma LLC $637 27 payments
  4. Collegium Pharmaceutical, Inc. $533 32 payments
  5. BIOTRONIK NRO, Inc. $330 24 payments
  6. Protega Pharmaceutials LLC $322 20 payments
  7. Scilex Pharmaceuticals Inc. $307 19 payments
  8. Boston Scientific Corporation $255 5 payments
  9. Pfizer Inc. $128 5 payments
  10. IBSA Pharma Inc. $87 4 payments
  11. Other $816 42 payments

Every payment, record by record

What the payments were for General payments · program years 2021–2025
  1. Food and Beverage $5,802 320 payments
Products named General payments · program years 2021–2025
  1. RELISTOR Gastroenterology $1,130 63 payments
  2. UBRELVY $1,022 66 payments
  3. QULIPTA $734 43 payments
  4. PROLATE Pain $616 26 payments
  5. PROLATE Pain $616 26 payments
  6. PROLATE Pain $616 26 payments
  7. NALOCET $616 26 payments
  8. RELISTOR Gastroenterology $518 27 payments
  9. PROLATE Pain $405 16 payments
  10. ROXYBOND $322 20 payments
  11. Other $3,121 168 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 41 drugs

Part D claims

3,443

Median for Nurse Practitioner: 389

Drug cost

$192,157

Median for Nurse Practitioner: $21,885

Branded share of claims

40.8%

Median for Nurse Practitioner: 19.6%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Belbuca Buprenorphine Hcl Brand 34 $24,682
Symproic Naldemedine Tosylate Brand 43 $19,362
Oxycodone-Acetaminophen Oxycodone Hcl/Acetaminophen Brand 454 $18,886
Ztlido Lidocaine Brand 37 $16,479
Hydrocodone-Acetaminophen Hydrocodone/Acetaminophen Brand 512 $14,182
Movantik Naloxegol Oxalate Brand 35 $14,114
Diclofenac Sodium Generic 38 $11,580
Oxycodone Hcl Generic 514 $11,473
Xtampza Er Oxycodone Myristate Brand 30 $10,120
Lidocaine Generic 117 $9,591

The 10 drugs with the highest cost, of 41 counted.

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 229,976 Part D prescribers listed as Nurse Practitioner; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 7 billing codes

Paid by Medicare

$80,469

Medicare's payments for the services billed

Medicare patients

228

Average age 72

Services billed

1,642

150 women, 78 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
High blood pressure 75%
Arthritis 75%
Diabetes 40%
Ischemic heart disease 33%
Depression 33%
Chronic kidney disease 25%
COPD 21%
Atrial fibrillation 18%

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Payments and prescribing

First 5 of 12 products · payments 2024

Two separate records. The payments come from Open Payments and the claims from Medicare. They are set side by side because they name the same product; they do not show that a payment affected a prescription.

Products this doctor was paid in connection with in 2024, beside Medicare claims for the same product
Product Paid by Related payments Part D claims Part B services
PROLATE
  • Forte Bio-Pharma LLC $216
$216 — —
ZTLido
  • Scilex Pharmaceuticals Inc. $165
$165 37 —
ROXYBOND
  • PROTEGA PHARMACEUTIALS LLC $162
$162 — —
UBRELVY
  • AbbVie, Inc. $162
$162 — —
QULIPTA
  • AbbVie, Inc. $162
$162 — —

A dash means Medicare published no figure for this doctor and product — fewer than 11 claims, or the product is not covered under that part — which is not the same as none. Payments are general payments only; one that names several products is split evenly between them, so an amount is payments related to the product, not money paid for it.

See all 12 in the dashboard with a free account

Records

320 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Nurse Practitioner, Family in Nevada

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record